chevron_leftBack
As of 14 June 2026, Cingulate Inc. has a market cap of $54.77M USD, ranking #29941 globally and #4400 in the United States.
It ranks #2709 in the Healthcare sector, and #956 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$54.77MUSD
Enterprise Value
$52.26MUSD
EBITDA (TTM)
-$19.4MUSD
Net Income (TTM)
-$22.45MUSD
PB Ratio
13.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Shane Schaffer
open_in_new
Employees
14
Founded
2012
IPO
08 Dec 2021
Website
cingulate.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.6% | -16% | -26% | -20% | 29% | 8.3% |
News
Loading...
CING Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
CING
Cingulate Inc
ISIN: US17248W3034
Shares Out.:
Shares Outstanding:
13.469M1
Shares Float:
11.03M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
4.71 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Cingulate Inc.
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
1M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
999K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
658K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
500K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
273K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
215K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
587K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
527K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
501K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
332K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
201K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
198K%
80.96B GBP
|
14.6
|
chevron_leftBack